Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...
Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing ...
Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...
Morning Overview on MSN
Researchers think they’ve found a path to restoring human vision
For decades, restoring sight after severe eye damage sat firmly in the realm of science fiction. Now a wave of converging ...
The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...
The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...
Oculis Holding (OCS) added ~11% on Tuesday after the Swiss drug developer announced the breakthrough therapy designation for ...
Glaucoma is a blinding disease caused by damage to the optic nerve, leading to permanent vision loss. The main risk factor is ...
Cold weather can significantly worsen multiple sclerosis symptoms, triggering stiffness, fatigue, and reduced mobility.
Collaborating institutions in Taiwan report higher risks of atopic disease among children conceived via assisted reproductive ...
An OU Health eye specialist explains who is most at risk, why symptoms are rare, and how early exams can prevent permanent ...
In some parts of the world, record numbers of people are being diagnosed with attention deficit hyperactivity disorder (ADHD). In the United States, for example, government researchers last year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback